smartcybers786@gmail.com 
A logo is pictured outside a building of the World Health Organization (WHO). — Reuters/File
#Pakistani #medicines #prequalified
ISLAMABAD: Despite being one of the major pharmaceutical manufacturing countries in the region, Pakistan currently has only four medicines or treatment products that are presented by the World Health Organization (WHO), a global recognized stamp of standard, safety and utility.
Similarly, no Pakistani drug or treatment products have been approved by the American Food and Drug Administration (FDA) or any other rigorous regulatory authority (SRA) in the world, which has highlighted a significant difference in the global regulatory identity.
Officials and experts are now demanding the country’s pharmaceutical sector to overcome and follow its hesitation that deployed to ensure the quality of medicines, increase reputation and unlock international markets for exports.
Which plays an important role in the global drug procurement through UN agencies such as UNICEF, UNIDS, and the World Fund. Without this identity, locally manufactured medicines are ineligible for international tenders, especially for life -saving treatments such as HIV/AIDS and anti -tuberculosis (TB) drug viral therapy (ARV).
“Pakistani pharmaceutical companies are reluctant to go through the WHO. Mainly due to cost and strict regulatory requirements,” “Local pharmaceutical companies fear that they cannot compete with Indian and Chinese manufacturers who produce more costs due to access to cheap raw materials and larger economies.”
However, the official emphasized that the prejudice of the global recognition is essential, especially in the field of vaccine and biological products.
He added, “The vaccine is purchased only by the WHO by international health agencies. Pakistani companies should cooperate with international vaccine and biological product manufacturers to start local production and deploy.”
Highlighting the stories of success, the official said that Pharmovo has become the first Pakistani company to win zinc sulphate verbal solutions and zinc sulphate -shotback pills, which will lead Pakistan to the first country globally oral solutions and the fourth low and middle income country.
The headquarters in Karachi, Pharmevo, received technical support from PQM+ throughout the process, which helped them accelerate the timeline and reduce costs. Remington Pharmaceuticals was Pakistan’s first national -owned company, which was deployed for its Anti -TB Product Lifofloxine for 250 mg coated tablets.
Who can save only two pharmaceutical concerns in Pakistan?
Despite these achievements, officials said that only four who have presented drugs or treatment products from Pakistan, which is significantly lower for the country with more than 700 pharmaceutical manufacturers.
The WHO’s precision program includes a five -step process, which includes the final approval of the quality based on the quality of the dose submission, the technical diagnosis, the inspection of manufacturing sites, and the quality of good manufacturing practice (GMP). Although this figure can be completed within three months when it is completed, the process of compliance often takes longer. At the recent high -level meeting, which includes Drip, who included the Ministry of National Health Services, and others, officials revealed that 124 of the 147 WHOs are manufactured in India in India. In Pakistan, locally registered but illegal drugs only meet 30 % of the need for national treatment.
WHO and UN AIDS have repeatedly called on Pakistan to start local production of HIV and TB medicines to reduce the dependence on Indian imports during tension trade relations. Which has helped upgrade its regulatory capacity to reach the World Benchmarking Tool (GBT) level 3, which is a prerequisite for global confidence in the regulatory systems.
UNIDS Country Director Heart Czechoco praised the government’s efforts and urged the provinces to add ARV and OPED treatment to their essential drug lists to enable direct and sustainable purchases for weak populations.
DRAP, DRAP, will soon issue a call to express interest from local manufacturers for which HIV, TB, and malaria medicines will be offered. Who and the partner agencies will provide technical consultations and support to accelerate this process and enhance the industry’s confidence.
